

Treatment Patterns for del(17P)/Mutated *TP53* or Relapsed/Refractory (R/R) CLL Among Experts and Lower-Volume Treaters

Poster Board P4
Abstract 501

Ryan P. Topping, PhD¹; Timothy A. Quill, PhD²; Farrukh T. Awan, MD, MS, MBA³; Jennifer R. Brown, MD, PhD³; Nicole Lamanna, MD⁴; Sameer A. Parikh, MBBS⁵; and Jennifer A. Woyach, MD⁶

1. Clinical Care Options, Reston, VA, USA. email: rtopping@clinicaloptions.com. 2. University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Dana-Farber Cancer Institute, Boston, MA, USA. 4. NewYork-Presbyterian/Columbia University Medical Center, New York, NY, USA. 5. Mayo Clinic, Rochester, MN, USA. 6. The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Background

- Targeted treatment options have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL), but oncology healthcare professionals (HCPs) who provide care for fewer numbers of patients with CLL are challenged to remain current with continuously changing treatment paradigms

Aim


- To assess ongoing educational needs, we analyzed the treatment choices made by HCPs in an online survey for select cases of poor-prognosis CLL and compared these with the choices of experts in CLL treatment for the same cases

Methods

- As part of a CME program, HCPs could access an online algorithm to enter specific characteristics of a CLL case scenario and receive treatment recommendations from 5 US-based CLL experts
- Experts made recommendations in July 2024 for 146 possible case scenarios built into the algorithm
- Case scenarios were defined by factors the expert panel considered important for treatment selection, including prior treatment, the presence of del(17p) or a *TP53* or *IGHV* mutation, and age/fitness
- After entering their case characteristics, HCPs were asked to enter their planned treatment prior to viewing the expert recommendations
- We compared expert and HCP treatment choices across various case scenarios that were entered into the algorithm between August 2024 and February 2025, with a focus on previously untreated CLL with del(17p)/mutated *TP53* or R/R CLL

Results: Participant and Case Demographics

- 346 patient cases entered by 174 HCPs



- 231 cases of previously untreated CLL entered; 91 (39%) sought recommendations for del(17p)/mutated *TP53* disease


Conclusions

An analysis of data from an online interactive decision support tool demonstrated considerable variance in treatment recommendations among experts and lower-volume treaters for patients with higher-risk CLL


Our findings provide insight into potential educational needs among HCPs who manage patients with CLL, suggesting that targeted expert-led education could benefit these HCPs

Results: Impact of Expert Recommendations

Did the expert recommendations change your treatment choice?




I used this tool to get expert recommendations on:




Results: HCP vs Expert Treatment Selections for Specific Case Scenarios



Newly Diagnosed del(17p)/*TP53* Mutated CLL, No Significant Comorbidities



Newly Diagnosed del(17p)/*TP53* Mutated CLL; History of Cardiac Arrhythmias, Presence of Cardiac Failure, Receiving Anticoagulation Therapy or Doublet Antiplatelet Therapy, or Uncontrolled Hypertension



R/R After Venetoclax + Anti-CD20 Ab (<2 Years After Completion of Treatment) and a Covalent BTKI



†Including the US, EU, and Japan.



*Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without permission from ASCO or the author of this poster.

Supported by educational grants from AbbVie Inc.; AstraZeneca; Beigene, Ltd., and Bristol Myers Squibb.